EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

A Monoclonal Antibody ELISA–Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines

Marcus Odin iD, Falko Schmeisser, Jackeline Soto, Jerry P Weir

Influenza and Other Respiratory Viruses · 2026-03 · 20 (3)

DOI: 10.1111/irv.70206 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 25.02.2026. Verfasst von Marcus Odin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Mar…. Hauptthemen laut MEDLINE: Vaccine Potency, Influenza Vaccines, Influenza, Human. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The single radial immunodiffusion (SRID) assay is used to determine the potency of inactivated influenza vaccines. Nevertheless, development of alternative influenza vaccine potency assays with greater sensitivity and less reliance on large quantities of reference reagents is needed. Many candidate alternative potency assays use monoclonal antibodies (mAbs) to quantify the relevant immunogenic form of HA in vaccines. Although the feasibility of such assays has been demonstrated, concerns remain as to whether the necessary antibody reagents can be generated in the timeframes of vaccine manufacture, particularly for pandemic vaccines.

Methods

We describe the development and evaluation of a mAb‐based ELISA assay to measure the potency of several candidate H5 clade 2.3.4.4b A/Astrakhan/3212/2020 influenza vaccines prepared recently in response to the ongoing H5N1 outbreak in the United States. The assay uses H5 mAbs that were generated and characterized several years prior to the emergence of these H5N1 viruses.

Results

Correlation of the ELISA potency results with traditional SRID potency values was excellent for a cell‐based vaccine and one egg‐based vaccine. The ELISA and SRID potency values for the second egg‐based vaccine were not as well aligned initially, but alignment was improved by use of an internal standard.

Conclusions

The results demonstrated that the ELISA potency assay is suitable for determining the potency of inactivated H5 A/Astrakhan/3212/2020 influenza vaccines. Moreover, the results demonstrate the importance of preparing libraries of antibody reagents for influenza subtypes with pandemic potential so that suitable mAbs are available for development of alternative mAb vaccine potency assays when needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine PotencyInfluenza VaccinesInfluenza, HumanAntibodies, MonoclonalEnzyme-Linked Immunosorbent AssayPandemicsHumansVaccines, InactivatedSensitivity and SpecificityInfluenza A Virus, H5N1 SubtypeUnited StatesInfluenza A Virus, H5N8 SubtypeHemagglutinin Glycoproteins, Influenza Virus

Stichwörter der Autor:innen

H5influenzavaccine potency

Substanzen

Antibodies, MonoclonalInfluenza VaccinesVaccines, InactivatedHemagglutinin Glycoproteins, Influenza Virus

Autor:innen und Institutionen

  • Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Marcus Odin

Förderung

  • US Department of Health and Human Services
  • Administration for Strategic Preparedness and Response
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Odin, M., Schmeisser, F., Soto, J., & Weir, J. P. (2026). A Monoclonal Antibody ELISA–Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines. Influenza and Other Respiratory Viruses, 20(3). https://doi.org/10.1111/irv.70206

Vancouver

Odin M, Schmeisser F, Soto J, Weir JP. A Monoclonal Antibody ELISA–Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines. Influenza and Other Respiratory Viruses. 2026;20(3). doi:10.1111/irv.70206

BibTeX
@article{Odin2026,
  author = {Odin, Marcus and Schmeisser, Falko and Soto, Jackeline and Weir, Jerry P},
  title = {A Monoclonal Antibody ELISA–Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  volume = {20},
  number = {3},
  doi = {10.1111/irv.70206}
}
Kostenlos starten →